secwatch.observer — SEC 8-K summary
======================================

Issuer:     Co-Diagnostics, Inc. (CODX)
CIK:        0001692415
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001493152-23-027534
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revenue collapse to $0.2M, Q2 net loss $8.9M vs $2.7M a year ago
----------------------------------------------------------------

- Revenue $0.2M vs $5.0M in prior-year quarter as COVID test demand declined.
- Operating loss of $12.0M increased from $4.1M on pre-commercialization investments in Co-Dx PCR Home platform.
- Net loss $8.9M ($0.31 per share loss) compared to $2.7M loss ($0.08 per share) a year ago.
- Cash and securities $69.1M; repurchased 0.4M shares at avg $1.51 for ~$0.6M.
- Received $1.2M NIH RADx grant and over $2.3M from Gates Foundation for TB/HPV test development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692415/000149315223027534/0001493152-23-027534-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692415/000149315223027534/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-027534

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer